Druggable epigenetic suppression of interferon-induced chemokine expression linked to <i>MYCN</i> amplification in neuroblastoma

Abstract

Our results delineate a strategy for targeted epigenetic immunomodulation of high-risk NBs, whereby EHMT inhibitors alone or in combination with EZH2 inhibitors (in particular, <i>MYCN</i>-amplified NBs) could promote a T-cell-infiltrated TME via enhanced Th1-type chemokine expression.